Intestinal Obstruction

Categories: Fetal diseases, Gastrointestinal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Intestinal Obstruction

Summaries for Intestinal Obstruction

MedlinePlus: 41 An intestinal obstruction occurs when food or stool cannot move through the intestines. The obstruction can be complete or partial. There are many causes. The most common are adhesions, hernias, cancers, and certain medicines. Symptoms include: Severe abdominal pain or cramping Vomiting Bloating Loud bowel sounds Swelling of the abdomen Inability to pass gas Constipation A complete intestinal obstruction is a medical emergency. It often requires surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Intestinal Obstruction, also known as inspissated milk syndrome, is related to ileus and hirschsprung disease 1, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Intestinal Obstruction is SLC26A3 (Solute Carrier Family 26 Member 3), and among its related pathways/superpathways are Signal Transduction and Cytoskeletal Signaling. The drugs Dexmedetomidine and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include kidney, small intestine and colon, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Related Diseases for Intestinal Obstruction

Diseases in the Intestinal Obstruction family:

Intestinal Pseudo-Obstruction

Diseases related to Intestinal Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 900)
# Related Disease Score Top Affiliating Genes
1 ileus 32.4 GUCY2C CRP CFTR
2 hirschsprung disease 1 32.1 RET NRTN GDNF EDNRB EDN3 ACTG2
3 intestinal pseudo-obstruction 31.7 SGO1 RET FLNA EDNRB EDN3 CFTR
4 rectal benign neoplasm 31.2 KRT7 KRT20 CDX2
5 lymphangioma 31.1 KRT7 KRT20 CDX2 CD8A
6 colonic benign neoplasm 31.0 KRT7 KRT20 CDX2 CD8A
7 intestinal perforation 31.0 NOD2 KRT7 CRP CD8A
8 intestinal tuberculosis 30.9 NOD2 CRP
9 pseudomyxoma peritonei 30.8 KRT7 KRT20 CDX2
10 diarrhea 30.7 SLC26A3 NOD2 MVK GUCY2C CFTR
11 familial mediterranean fever 30.7 NOD2 MVK CRP
12 small intestine cancer 30.7 KRT7 KRT20 CDX2
13 megacolon 30.7 RET NRTN GDNF EDNRB EDN3
14 appendix adenocarcinoma 30.6 KRT7 KRT20 CDX2
15 cystic teratoma 30.6 KRT7 KRT20 CDX2
16 neuroendocrine tumor 30.6 RET MTOR KRT20 CDX2
17 megacystis-microcolon-intestinal hypoperistalsis syndrome 1 30.6 SGO1 FLNA ACTG2
18 enterocolitis 30.4 NOD2 CRP
19 hemorrhoid 30.4 KRT7 KRT20 CRP
20 adenoma 30.4 SLC26A3 RET KRT7 KRT20 CDX2
21 small intestine adenocarcinoma 30.4 KRT7 CDX2
22 cholangiocarcinoma 30.4 MTOR KRT7 KRT20 CDX2
23 jejunal adenocarcinoma 30.3 KRT7 CDX2
24 hydronephrosis 30.3 KRT7 CRP ACTG2
25 sigmoid neoplasm 30.3 KRT7 KRT20 CDX2
26 signet ring cell adenocarcinoma 30.3 KRT7 KRT20 CDX2
27 mucinous adenocarcinoma 30.3 KRT7 KRT20 CDX2
28 behcet syndrome 30.3 NOD2 MVK CRP CD8A
29 ascending colon cancer 30.3 KRT7 CDX2
30 ampulla of vater adenocarcinoma 30.3 KRT7 KRT20 CDX2
31 mucinous cystadenocarcinoma 30.3 KRT7 KRT20 CDX2
32 benign teratoma 30.3 KRT7 KRT20 CDX2
33 cystic kidney disease 30.2 MTOR EDNRB CRP CFTR
34 cystitis 30.2 KRT7 KRT20 CRP
35 abdominal tuberculosis 30.2 NOD2 CRP CD8A
36 exanthem 30.1 MTOR CRP CD8A
37 pheochromocytoma 30.1 RET KRT7 GDNF EDN3 CRP
38 cholangitis 30.0 NOD2 KRT7 CRP CFTR
39 vesicoureteral reflux 29.9 RET GDNF CRP
40 meconium ileus 11.7
41 volvulus of midgut 11.3
42 paralytic ileus 11.2
43 peritonitis 11.2
44 colonic atresia 11.2
45 intestinal pseudoobstruction, neuronal, chronic idiopathic, x-linked 11.2
46 ascaris lumbricoides infection 11.2
47 omphalomesenteric cyst 11.2
48 santos mateus leal syndrome 11.2
49 crohn's disease 11.1
50 jejunal atresia 11.1

Comorbidity relations with Intestinal Obstruction via Phenotypic Disease Network (PDN): (show top 50) (show all 57)

Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Acute Vascular Insufficiency of Intestine Anxiety
Ascending Colon Cancer Bronchitis
Candidiasis Cecal Benign Neoplasm
Cervical Cancer Chronic Intestinal Vascular Insufficiency
Chronic Kidney Disease Chylomicron Retention Disease
Colorectal Cancer Crohn's Disease
Decubitus Ulcer Deficiency Anemia
Descending Colon Cancer Enterovesical Fistula
Esophageal Disease Esophagitis
Familial Atrial Fibrillation Gastric Cancer
Gastrointestinal System Cancer Generalized Atherosclerosis
Heart Disease Hepatic Flexure Cancer
Hydronephrosis Hypertension, Essential
Hypothyroidism Inflammatory Bowel Disease 1
Intestinal Disease Intestinal Perforation
Iron Deficiency Anemia Irritable Bowel Syndrome
Jejunal Cancer Kidney Disease
Marasmus Neutropenia
Osteoporosis Ovarian Cancer
Pancreatic Cancer Pancreatitis, Hereditary
Paralytic Ileus Peritonitis
Postgastrectomy Syndrome Protein-Energy Malnutrition
Radiation Cystitis Rectosigmoid Junction Neoplasm

Graphical network of the top 20 diseases related to Intestinal Obstruction:

Diseases related to Intestinal Obstruction

Symptoms & Phenotypes for Intestinal Obstruction

UMLS symptoms related to Intestinal Obstruction:

nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

GenomeRNAi Phenotypes related to Intestinal Obstruction according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.17 ACTG2 CD8A CDX2 CFTR CRP EDN3
2 no effect GR00402-S-2 10.17 ACTG2 CDX2 CFTR CRP EDN3 EDNRB

MGI Mouse Phenotypes related to Intestinal Obstruction:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 ACTG2 CDX2 CFTR CRP EDNRB FLNA
2 endocrine/exocrine gland MP:0005379 10.03 CD8A CDX2 CFTR EDNRB GDNF MTOR
3 digestive/alimentary MP:0005381 9.93 CDX2 CFTR EDN3 EDNRB FLNA GDNF
4 cellular MP:0005384 9.77 CD8A CDX2 CFTR EDNRB FLNA GDNF
5 mortality/aging MP:0010768 9.5 CD8A CDX2 CFTR EDN3 EDNRB FLNA

Drugs & Therapeutics for Intestinal Obstruction

Drugs for Intestinal Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605 16129706
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
Morphine Approved, Investigational Phase 4 57-27-2 5288826
11 Adrenergic alpha-Agonists Phase 4
12 Adrenergic Agonists Phase 4
13 Adrenergic Agents Phase 4
14 Anesthetics, Intravenous Phase 4
15 Anesthetics, General Phase 4
16 Hypnotics and Sedatives Phase 4
17 Analgesics, Non-Narcotic Phase 4
18 Hormones Phase 4
19 Hormone Antagonists Phase 4
20 Excitatory Amino Acid Antagonists Phase 4
21 Anesthetics, Dissociative Phase 4
22 Neuromuscular Nondepolarizing Agents Phase 4
23 Neuromuscular Blocking Agents Phase 4
24 Anesthetics Phase 4
25 Analgesics Phase 4
26 Anti-Inflammatory Agents, Non-Steroidal Phase 4
27 Anti-Inflammatory Agents Phase 4
28 Narcotics Phase 4
29 Anesthetics, Local Phase 4
30 Analgesics, Opioid Phase 4
Naloxone Approved, Vet_approved Phase 3 465-65-6 5284596
Lanreotide Approved Phase 3 108736-35-2 71349 6918011
Phenobarbital Approved, Investigational Phase 3 50-06-6 4763
Metronidazole Approved Phase 3 443-48-1, 69198-10-3 4173
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
Cefuroxime Approved Phase 3 55268-75-2 5479529
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
Clavulanic acid Approved, Vet_approved Phase 3 58001-44-8 5280980
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
41 Narcotic Antagonists Phase 3
42 Antibiotics, Antitubercular Phase 3
43 Anti-Bacterial Agents Phase 3
44 Anti-Infective Agents Phase 3
45 Anticonvulsants Phase 3
46 GABA Modulators Phase 3
47 Antiprotozoal Agents Phase 3
48 Antiparasitic Agents Phase 3
Cefuroxime axetil Phase 3 3379942
50 beta-Lactamase Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Ketofol vs Dexmedetomidine for Preventing Post-operative Delirium in Elderly Patients Undergoing Intestinal Obstruction Surgeries. A Randomized Controlled Study Completed NCT04816162 Phase 4 ketofol;dexmedetomidine
2 Phase 4 Evaluation of SurgiWrapTM to Minimize Soft Tissue Attachment & Reduce the Incidence of Early Post-Operative Bowel Obstruction in Colorectal Surgery Completed NCT00531739 Phase 4
3 Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel Obstruction Completed NCT00389116 Phase 4 gastrograffin;water
4 Gastrografin Use in Small Bowel Obstruction Caused by Adherences Completed NCT00601809 Phase 4 Gastrografin®: G
5 Effect of Deep Versus Moderate Neuromuscular Blockade on Peak Airway Pressures During Elective Laparoscopic Surgery Completed NCT02812186 Phase 4 Rocuronium
6 Prospective, Multi-centers, Investigator Sponsored, Randomized Controlled Trial Towards Identifying the Effect of Somatostatin Treatment in Early Postoperative Simple Small Bowel Obstruction Completed NCT01082627 Phase 4 Somatostatin
7 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy Completed NCT01507246 Phase 4 IV morphine sulfate;EXPAREL (bupivacaine liposome injectable suspension)
8 The Effects of Preoperative High-dose Dexamethasone on Inflammatory Response and Recovery After Emergency Laparotomy, a Randomized, Double-blind, Placebo-controlled Clinical Trial - AHA STEROID TRIAL Recruiting NCT04791566 Phase 4 Dexamethasone 1 mg/kg;Physiologic saline
9 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation of Bupivacaine, EXPAREL(R): A Phase 4 Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy (IMPROVE-Lap Colectomy) Terminated NCT02058290 Phase 4 IV morphine sulfate or Sponsor-approved equivalent;EXPAREL
10 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy Terminated NCT01507233 Phase 4 IV morphine sulfate;EXPAREL (bupivacaine liposome injectable suspension)
11 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy Terminated NCT01507220 Phase 4 morphine sulfate;bupivacaine liposome extended-release injectable suspension
12 The Use of Gastrografin to Help Alleviate Bowel Obstruction Related to Poor Bowel Motility in Gastroschisis Patients. Withdrawn NCT03334578 Phase 4 Gastrografin
13 Prospective Multicenter Trial for Anti-adhesion Effect of GUARDIX-SGⓇ Following Radical Gastrectomy in Patients With Gastric Cancer. Unknown status NCT02198898 Phase 3
14 Endolaparoscopic Versus Immediate Surgery for Obstructing Colorectal Cancers: A Randomised Trial Unknown status NCT00164879 Phase 3
15 A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase IIB Study of Oral Naloxone for the Treatment of Opioid-Induced Constipation in Patients With Chronic, Non-malignant Pain or Malignant Pain Unknown status NCT00020605 Phase 3 naloxone hydrochloride
16 Effects of Delayed Enteral Nutrition on Inflammatory Responses and Immune Function Competence in Critically Ill Patients With Prolonged Fasting Completed NCT01834430 Phase 3
17 Endoscopic Stenting and Elective Surgery Versus Emergency Surgery for Left-sided Malignant Colonic Obstruction: A Prospective Randomized Trial. Completed NCT00758186 Phase 3
18 Phase III, Multicentre, Randomised, Double-blind, Comparative Study to Assess the Efficacy and Safety of Lanreotide 30 mg Versus Placebo as a Palliative Treatment of Clinical Symptoms Associated With Intestinal Obstruction Due to Peritoneal Carcinomatosis in Inoperable Patients. Completed NCT00216372 Phase 3 Lanreotide (microparticle formulation)
19 Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction in Patients With Gastric Cancer. A Randomized Clinical Trial Completed NCT00529412 Phase 3
20 Outcome of Palliative Management of Malignant Large Bowel Obstruction With Colorectal Stents or Surgery Completed NCT00140868 Phase 3
21 Phase 3 Study of Antibiotic Prophylaxis Use Prior Emergent Surgery, Because of Acute Appendicitis Completed NCT01524081 Phase 3 Metronidazole, Cefuroxime;Amoxicillin (+ clavulanic acid) and Fluconazole;Placebo
22 The Therapeutic Role of Gastrografin for Treating Small Bowel Obstruction in Children: A Multi-Centre Canadian Prospective Study Recruiting NCT03573921 Phase 2, Phase 3 Gastrografin
23 A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in the Prevention of Acute Enteritis in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy Withdrawn NCT01473290 Phase 3
24 An International, Multicentric, Prospective, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 MG Associated to Standard of Care in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction Completed NCT02275338 Phase 2 Lanreotide Autogel
25 Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis Completed NCT00332696 Phase 2 Octreotide LAR;Octreotide (Immediate release);methylprednisolone;Placebo
26 Prospective Study to Assess the Efficacy and Safety of Lanreotide 120 mg as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients Completed NCT01076803 Phase 2 Lanreotide (acetate)
27 Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study Completed NCT00004895 Phase 2 octreotide acetate
28 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
29 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
30 A Phase II, Non-Randomized, Multi-Cohort Trial of Docetaxel, Oxaliplatin and 5-Fluorouracil in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis and Inoperable Malignant Bowel Obstruction Recruiting NCT04840264 Phase 2 Docetaxel;Oxaliplatin;5Fluorouracil
31 A Phase II, Multicentre, Randomized Controlled Study Evaluating The Quality Of Life In Patients With Inoperable Malignant Bowel Obstruction Treated With Lanreotide Autogel 120 mg in Combination With Standard Care vs. Standard Care Alone (QOL IN IMBO STUDY) Terminated NCT02365584 Phase 2 lanreotide (Autogel formulation)
32 Prospective, Randomized Trial Comparing Early Laparoscopic Enterolysis Versus a Time-limited Trial of Nonoperative Management for High-grade Small Bowel Obstruction Terminated NCT02692638 Phase 2
33 Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open Label, Phase-2 Study at an NCI Comprehensive Cancer Center Terminated NCT04027348 Phase 2 Dexamethasone;Metoclopramide;Octreotide
34 Phase I/II Trial of Best Supportive Care and Chemotherapy, Either Cisplatin or Paclitaxel, in Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Presenting With Inoperable Malignant Bowel Obstruction Terminated NCT01083537 Phase 1, Phase 2 Cisplatin;Paclitaxel
35 Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects Completed NCT01596777 Phase 1 Loperamide;Loperamide placebo;Methylnaltrexone placebo;Methylnaltrexone 12 mg sc.;Methylnaltrexone IR capsule;Methylnaltrexone ER capsule;Sulfasalazine
36 Effects of Extended Release Methylnaltrexone Bromide (150 mg b.i.d.) in Comparison to Extended Release Naloxone Hydrochloride (20 mg b.i.d.) on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time in Healthy Subjects. Completed NCT01596764 Phase 1 Loperamide placebo;Loperamide;Sulfasalazine;Placebo of MNTX and NLX;Naloxone;Methylnaltrexone
37 Therapeutic Oxygen for Gastrointestinal Atony (TOGA): Pilot Trial - Management of Acute Colonic Pseudo-Obstruction With Oxygen Supplementation Completed NCT03386136 Phase 1 100% Oxygen
38 Hypertonic Saline 3% Compared to Hypertonic Saline 1.8% for Fluid Management of Intestinal Obstruction Surgery Unknown status NCT03741257 Hypertonic saline
39 Ostomy in Continuity or Conventional Ileostomy for Complex Pediatric Intestinal Diseases: a Retrospective Multicentric Analysis Unknown status NCT04213976
40 Comparison the Hemodynamics Effects Between Dexmedetomidine and Propofol in Major Abdominal Surgical Patients Unknown status NCT01669044 dexmedetomidine;propofol
41 Prospective Multicenter Validation of a Clinicoradiological Score for Predicting the Severity of Strangulated Small Bowel Occlusion Unknown status NCT01125280
42 The Impact of Small Bowel Obstruction (SBO) on Quality of Life (QOL); the Efficacy of a Manual Physical Therapy to Improve QOL in Subjects With a History of SBO Unknown status NCT02639195
43 The BCAE Study: Best Care for Abdominal Emergencies Unknown status NCT04577339
44 Colonic Stenting With Elective Surgery Versus Emergency Surgery in the Management of Acute Malignant Colonic Obstruction: a Multicentre, Prospective, Open Label, Cohort Study Unknown status NCT01997684
45 Prospective Nationwide Audit of the Management of Adhesive Small Bowel Obstruction: a Snapshot Study Unknown status NCT03786159
46 Intrabdominal Pressure in Small Bowel Obstruction as a Possible Predictor for the Need of Operation Unknown status NCT01934283
47 Laparoscopic Versus Open Adhesiolysis for Small Bowel Obstruction - A Multicenter, Prospective, Randomized, Controlled Trial Unknown status NCT01867528
48 A Feasibility Study of Elemental Diet as an Alternative to Parenteral Nutrition for Patients With Inoperable Malignant Bowel Obstruction Unknown status NCT03150992
49 Nasogastric Tube Clamping Trial: Is it Useful? A Proposed Algorithm for Removal. Unknown status NCT04001985
50 Ultrasound Emergency Diagnosis of Small Bowel Obstruction. An Observational Study Unknown status NCT03226665

Search NIH Clinical Center for Intestinal Obstruction

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Heavy mineral oil
Mineral Oil
Mineral Oil, Light

Cochrane evidence based reviews: intestinal obstruction

Genetic Tests for Intestinal Obstruction

Genetic tests related to Intestinal Obstruction:

# Genetic test Affiliating Genes
1 Intestinal Obstruction 28

Anatomical Context for Intestinal Obstruction

Organs/tissues related to Intestinal Obstruction:

MalaCards : Kidney, Small Intestine, Colon, Pancreas, Appendix, Lymph Node, Liver

Publications for Intestinal Obstruction

Articles related to Intestinal Obstruction:

(show top 50) (show all 12644)
# Title Authors PMID Year
Variants in ACTG2 underlie a substantial number of Australasian patients with primary chronic intestinal pseudo-obstruction. 5
29781137 2018
Familial visceral myopathy diagnosed by exome sequencing of a patient with chronic intestinal pseudo-obstruction. 5
24777424 2014
Segregation of a missense variant in enteric smooth muscle actin γ-2 with autosomal dominant familial visceral myopathy. 5
22960657 2012
Update on SLC26A3 mutations in congenital chloride diarrhea. 5
21394828 2011
Primary 'False' Enterolith: A rare cause of small bowel obstruction. 41
36407705 2022
Colonic obstruction secondary to lithobezoar in a child. 41
36405655 2022
Comment on "Do biomarkers have predictive value in the treatment modality of the patients diagnosed with bowel obstruction?" 41
36417634 2022
Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies. 53 62
18782827 2008
Impact of nutrition on phenotype in CFTR-deficient mice. 53 62
17805210 2007
Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. 53 62
17030173 2006
Distinct pattern of lung gene expression in the Cftr-KO mice developing spontaneous lung disease compared with their littermate controls. 53 62
16418321 2006
Distal intestinal obstruction syndrome in adults with cystic fibrosis. 53 62
15181619 2004
Liver cirrhosis and portal hypertension in cystic fibrosis. 53 62
14501614 2003
Gdnf haploinsufficiency causes Hirschsprung-like intestinal obstruction and early-onset lethality in mice. 53 62
11774071 2002
Cellular localization of the cystic fibrosis transmembrane conductance regulator in mouse intestinal tract. 53 62
10959824 2000
[Gastrointestinal complications of adult patients with cystic fibrosis]. 53 62
10494610 1999
Clinical and genetic risk factors for cystic fibrosis-related liver disease. 53 62
9917439 1999
Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. 53 62
8589719 1996
Useful classification of intussusception for preoperative 3D-MDCT images, type M or W: a case report and a novel classification. 62
36439929 2023
High-quality read-based phasing of cystic fibrosis cohort informs genetic understanding of disease modification. 62
36386424 2023
Hand-Sewn Versus Stapled Small Bowel Anastomoses in Patients With Secondary Mesenteric Ischemia. 62
36115149 2023
Hyperglycaemia and the risk of post-surgical adhesion. 62
32536284 2022
Prevention of peritoneal adhesions formation by core-shell electrospun ibuprofen-loaded PEG/silk fibrous membrane. 62
35296208 2022
Acute abdomen due to strangulated intravesical hernia with incidental finding of kidney tumor: A case report and literature review. 62
36453785 2022
Costs Associated With Surgical Infections at a Tertiary Referral Hospital in Rwanda. 62
35964487 2022
From abdominal pain to a diagnosis of primary sclerosing encapsulating peritonitis and its management, a case report. 62
33502964 2022
Comparison of the Effectiveness of Transnasal Humidified Rapid Insufflation Ventilator Exchange (THRIVE) with Facemask Pre-Oxygenation in 40 Patients ≥65 Years of Age Undergoing General Anaesthesia During Gastrointestinal Surgery for Intestinal Obstruction. 62
36461619 2022
Idiopathic anomalous congenital band causing small intestinal obstruction in a 5-month-old dog. 62
36467375 2022
A rare cause of acute intestinal obstruction: Ileo-sigmoid knotting type IIA. 62
36389199 2022
Colonic sand impaction with cecal rupture and peritonitis in an adult African savanna elephant, and review of noninfectious causes of gastrointestinal disease in elephants. 62
36401512 2022
Laparoscopic Welti's Maneuver: A Single-Center Experience. 62
36445742 2022
Innovative Endoscopic Management of a Duodenal Web Using Balloon Dilatation and a Gastrojejunal Tube in an Infant with Complex Esophageal Atresia. 62
36445752 2022
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. 62
35304622 2022
[Risk factor and nomogram for predicting the probability of a permanent stoma after laparoscopic intersphincteric resection for ultralow rectal cancer]. 62
36396375 2022
[Effect of intestinal obstruction stent combined with neoadjuvant chemotherapy on the pathological characteristics of surgical specimens in patients with complete obstructive colorectal cancer]. 62
36396377 2022
Spontaneous Ogilvie's Syndrome in a Nonagenarian Male: A Study of a Rare Case With Literature Review. 62
36475136 2022
Left-Sided Colonic Tuberculosis Presenting as Colonic Stricture: A Rare Presentation of a Common Disease. 62
36447761 2022
Large Bowel Obstruction Secondary to a Fecaloma in a Child With Cerebral Palsy. 62
36475161 2022
Redo Gastric Bypass following internal herniation with gangrenous roux limb, in second trimester pregnancy: How safe? 62
36270206 2022
A 10 cm pedunculated duodenal Brunner gland hamartoma, case report and literature review. 62
36270207 2022
Filiform polyposis presenting with rapid growth and severe anemia case report. 62
36334548 2022
Meckel's diverticulum causing acute intestinal obstruction: A case series. 62
36381041 2022
Imaging congenital anomalies of the ileum in adults:a pictorial review. 62
36401130 2022
[Current status of influencing factors for postoperative anastomotic leakage in low rectal cancer]. 62
36396382 2022
Adult sigmoidorectal intussusception as an unexpected cause of lower gastrointestinal bleeding. 62
36412482 2022
Intestinal occlusion due to Burkitt lymphoma: an unusual cause. 62
35607925 2022
Blue rubber bleb nevus syndrome complicated with disseminated intravascular coagulation and intestinal obstruction: A case report. 62
36405278 2022
Effect of accelerated rehabilitation combined with enteral nutrition on gastrointestinal function recovery after hepatectomy. 62
35904638 2022
Embryology and anatomy of Hirschsprung disease. 62
36417785 2022
Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq. 62
36424614 2022

Variations for Intestinal Obstruction

ClinVar genetic disease variations for Intestinal Obstruction:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SLC26A3 NM_000111.3(SLC26A3):c.1000G>T (p.Glu334Ter) SNV Pathogenic
978618 rs1208952914 GRCh37: 7:107423769-107423769
GRCh38: 7:107783324-107783324
2 SLC26A3 NM_000111.3(SLC26A3):c.269_270dup (p.Gly91fs) DUP Pathogenic
55994 rs386833476 GRCh37: 7:107434187-107434188
GRCh38: 7:107793742-107793743
3 ACTG2 NM_001615.4(ACTG2):c.442C>T (p.Arg148Cys) SNV Likely Pathogenic
1177291 GRCh37: 2:74136257-74136257
GRCh38: 2:73909130-73909130
4 ERF NM_006494.4(ERF):c.1636C>T (p.Arg546Ter) SNV Uncertain Significance
599007 rs764412749 GRCh37: 19:42752628-42752628
GRCh38: 19:42248476-42248476
5 GATA4 NM_001308093.3(GATA4):c.94G>C (p.Ala32Pro) SNV Uncertain Significance
599008 rs773545065 GRCh37: 8:11565915-11565915
GRCh38: 8:11708406-11708406

Expression for Intestinal Obstruction

Search GEO for disease gene expression data for Intestinal Obstruction.

Pathways for Intestinal Obstruction

Pathways related to Intestinal Obstruction according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
2 11.95 KRT7 KRT20 FLNA ACTG2
Show member pathways

GO Terms for Intestinal Obstruction

Biological processes related to Intestinal Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane hyperpolarization GO:0060081 9.73 SLC26A3 CFTR
2 positive regulation of prostaglandin-endoperoxide synthase activity GO:0060585 9.71 NOD2 EDN3
3 intracellular pH elevation GO:0051454 9.67 SLC26A3 CFTR
4 vasoconstriction GO:0042310 9.63 CRP EDN3 EDNRB
5 vein smooth muscle contraction GO:0014826 9.62 EDNRB EDN3
6 posterior midgut development GO:0007497 9.56 RET EDNRB
7 enteric nervous system development GO:0048484 9.43 RET GDNF EDNRB
8 neural crest cell migration GO:0001755 9.32 RET NRTN GDNF EDNRB EDN3

Molecular functions related to Intestinal Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glial cell-derived neurotrophic factor receptor binding GO:0030116 8.92 NRTN GDNF

Sources for Intestinal Obstruction

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....